Commentary
Which trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitis

https://doi.org/10.1016/j.cmi.2023.03.021Get rights and content

Section snippets

Transparency declaration

TMW is a Wellcome Clinical Career Development Fellow (214560/Z/18/Z) and JAW is a Wellcome Sir Henry Dale Fellow (223253/Z/21/Z). The other authors declare that they have no conflict of interest to declare.

Financial report

No external funding was received for writing this article, although the authors would like to acknowledge the long-term support provided by the Wellcome Trust, UK, to the Vietnam Africa Asia Programme and the Programme's previous and ongoing TBM clinical trials.

First page preview

First page preview
Click to open first page preview

References (15)

There are more references available in the full text version of this article.

Cited by (0)

View full text